Marc-André Kasper

8PUBLICATIONS
50CO-AUTHORS
GlycoconjugatesMolecular targetsNeural engineeringComposite and hybrid materialsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 19, 2026
Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates.

Philipp Ochtrop, Anil P Jagtap, Jan G Felber

|Aug 20, 2025
TUB-010, a Novel Anti-CD30 Antibody-Drug Conjugate Based on Tub-Tag Technology, Widens the Therapeutic Window by Reducing Toxicity While Maintaining High Efficacy.

Marcus Gerlach, Saskia Schmitt, Philipp Cyprys

|Jul 16, 2025
TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile.

Annette M Vogl, Saskia Schmitt, Isabelle Mai

|May 05, 2025
Orthogonal Site-Specific Dual Bioconjugation of Aryl and Alkyl Thiols.

Mark A R de Geus, Christian E Stieger, Jan Vincent V Arafiles

|Oct 13, 2023
Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody-Drug Conjugates.

Saskia Schmitt, Paul Machui, Isabelle Mai

|Aug 18, 2022
Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML.

Maike Roas, Binje Vick, Marc-André Kasper

Pageof 2

Frequent Collaborators

7 joint publications

Christian P R Hackenberger

6 joint publications

Dominik Schumacher

5 joint publications

Saskia Schmitt

4 joint publications

Jonas Helma